Abstracts tagged "Sjogren’s syndrome and hydroxychloroquine"

Abstract Number: L10 • 2018 ACR/ARHP Annual Meeting
Clinical Efficacy of Leflunomide/Hydroxychloroquine Combination Therapy in Patients with Primary Sjogren’s Syndrome: Results of a Placebo-Controlled Double-Blind Randomized Clinical Trial
Timothy R.D.J. Radstake¹, Eefje H.M. van der Heijden², Frederique M. Moret³, Maarten R. Hillen⁴, Ana P. Lopes⁵, Toine Rosenberg⁶, Nard Janssen⁶, Aike A. Kruize⁷ and Joel A.G. van Roon³, ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Rheumatology and Clinical Immunology, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Rheumatology & Clinical Immunology/ Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁶Department of Oral-Maxillofacial Surgery, University Medical Center Utrecht, Utrecht, Netherlands, ⁷Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Primary Sjogren’s syndrome (pSS) is a systemic, progressive autoimmune disease characterized by secretory gland dysfunction which lacks effective therapy. Clinical trials in patients with…
Abstract Number: 2674 • 2016 ACR/ARHP Annual Meeting
Primary Sjögren’s Syndrome: Extraglandular Manifestations and Hydroxychloroquine Therapy
Julia Demarchi¹, Silvia Beatriz Papasidero², María Alejandra Medina³, Diana Klajn⁴, Rafael Chaparro del Moral², Oscar Luis Rillo⁵, María Victoria Martire⁶, Gloria Crespo⁷, Anastasia Secco⁸, Antonio Catalan Pellet⁶, Cristina Amitrano⁹, Catherine Crow¹⁰, Cecilia Asnal⁹, Paula Pucci⁹, Francisco Caeiro¹¹, Nadia Benzaquén¹¹, Juan Pablo Pirola¹¹, Marcela Colazo¹¹, M. Mayer¹², F. Zazzetti¹², S. Velez¹², J. C. Barreira¹³, Natalia Tamborenea¹⁴, M. L. Santiago¹⁴ and Laura Raiti¹⁵, ¹Rheumatology Deparment, Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina, ²Rheumatology Department, Rheumatology Unit, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ³Rheumatology Department, Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina, ⁴Research Committee, Research Committee, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ⁵Rheumatology Department, Hospital General de Agudos “Dr. Ignacio Pirovano”, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁶Rheumatology, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ⁷Hospital Bernardino Rivadavia, Ciudad Autónoma de Buenos Aires, Argentina, ⁸Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ⁹Rheumatology, Hospital Alemán, Buenos Aires, Argentina, ¹⁰Rheumatology, Hospital Alemán, Buenos aires, Argentina, ¹¹Rheumatology, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ¹²Hospital Británico, Buenos Aires, Argentina, ¹³Rheumatology Service, Hospital Británico, Buenos Aires, Buenos Aires, Argentina, ¹⁴Rheumatology, OMI, Buenos Aires, Argentina, ¹⁵Clínica Bessone, San Miguel, Argentina
Background/Purpose: The use of Hydroxychloroquine (HCQ) in Primary Sjögren's Syndrome (PSS) has been assessed in different studies over the last years, with conflicting results regarding…
Abstract Number: L9 • 2012 ACR/ARHP Annual Meeting
Inefficacy of Hydroxychoroquine in Primary Sjögren’s Syndrome: Results of the Joquer Randomized Placebo-Controlled Trial in Primary Sjögren’s Syndrome
Jacques-Eric Gottenberg¹, Philippe Ravaud², Xavier Puechal³, Véronique Le Guern⁴, Jean Sibilia⁵, Vincent Goeb⁶, C. Larroche⁷, JJ Dubost⁸, Stephanie RIST⁹, Alain Saraux¹⁰, Jacques Morel¹¹, Gilles Hayem¹², Eric Hachulla¹³, Aleth Perdriger¹⁴, D. Sene¹⁴, Charles Zarnitsky¹⁵, Elodie Perrodeau¹⁶, D. Batouche¹⁷, V. Furlan¹⁸, Joelle Benessiano¹⁹, Raphaèle Seror²⁰ and Xavier Mariette¹⁸, ¹Strasbourg University Hospital, Strasbourg, France, ²Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ³Internal Medicine, Hôpital Cochin, Paris, France, ⁴Department of Internal Medicine, Cochin Hospital, Paris, France, ⁵Rheumatology, CHU Hautepierre, Strasbourg, France, ⁶Rheumatology, Rouen University Hospital, Rouen, France, ⁷Hospital University Bobigny, bobigny, France, ⁸Rheumatology, CHU CLERMONT-FERRAND, Clermont-Ferrand, France, ⁹Orleans, Rhumatologie, ¹⁰Department of rheumatology and unit of immunology (EA 2216), Université Brest Occidentale, Brest, France, ¹¹Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France, ¹²Rheumatology Unit, Bichat Hospital, Paris, France, ¹³Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, ¹⁴Rheumatology, Hôpital Sud, Rennes, France, ¹⁵Rheumatology, Le Havre General Hospital, Le Havre, France, ¹⁶Epidemiologist, Paris, France, ¹⁷Paris, ¹⁸Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ¹⁹Rheumatology, Paris Unervisity Hospital BICHAT, Paris, France, ²⁰Rheumatology, Bicetre university hospital, LE Kremlin-Bicetre, France
Background/Purpose: Hydroxychloroquine (HQ, Plaquenil) is often prescribed in patients with primary Sjögren’s syndrome (pSS), notably for arthralgias, synovitis or purpura, but also only for dryness…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].